SAMD13: Potential Drug Target and Biomarker for Diseases (G148418)

Target Name: SAMD13

NCBI ID: G148418

SAMD13

SAMD13: Potential Drug Target and Biomarker for Diseases

SAMD13 (S-adenylase 13), also known as HSD-41, is a protein that is expressed in various tissues throughout the body. It is a key enzyme in the synthesis of adenosine, which is a molecule that plays a crucial role in various physiological processes. SAMD13 is also known as adenosine monophosphate synthase 41, or HSD41.

The SAMD13 gene was first identified in the 1990s, and it has since been shown to be expressed in a wide variety of tissues, including the brain, heart, liver, and muscle. It is also highly expressed in the placenta, which is a critical organ for the development and growth of fetuses.

One of the key functions of SAMD13 is its role in the synthesis of adenosine. Adenosine is a naturally occurring molecule that plays a crucial role in various physiological processes, including modulating pain, inflammation, and sleep-wake cycles. It is also involved in the regulation of ion channels and the modulation of gene expression.

SAMD13 is an enzyme that is expressed in the brain, heart, and liver, and it is highly expressed in the placenta. It is also involved in the synthesis of adenosine, which is a crucial molecule that plays a critical role in various physiological processes.

SAMD13 is a potential drug target, and several studies have suggested that it may be a useful biomarker for certain diseases. For example, SAMD13 has been shown to be involved in the development of certain types of cancer, including lung and ovarian cancer. It has has also been shown to be involved in the development of cardiovascular disease, including heart failure and hypertension.

In addition to its potential clinical applications, SAMD13 is also a potential biomarker for certain diseases. For example, it has been shown to be involved in the diagnosis of certain types of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. to be involved in the diagnosis of certain types of cardiovascular disease, including heart failure and hypertension.

SAMD13 is also a potential target for drug development, and several studies have suggested that it may be a useful drug for the treatment of certain types of diseases. For example, SAMD13 has been shown to inhibit the activity of certain enzymes that are involved in the synthesis of adenosine, which may make it a useful treatment for certain types of cancer. It has also been shown to increase the levels of certain molecules in the brain, which may make it a useful treatment for certain types of neurodegenerative diseases.

Overall, SAMD13 is a protein that is expressed in various tissues throughout the body and is involved in the synthesis of adenosine. It is a potential drug target and biomarker for a wide variety of diseases. Further research is needed to fully understand its role in these processes and to develop effective treatments.

Protein Name: Sterile Alpha Motif Domain Containing 13

The "SAMD13 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SAMD13 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets